164 related articles for article (PubMed ID: 31490575)
1. The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin.
Jones A; McGrath S; Gustafson DL
J Vet Pharmacol Ther; 2019 Nov; 42(6):588-592. PubMed ID: 31490575
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology.
Pastina B; Early PJ; Bergman RL; Nettifee J; Maller A; Bray KY; Waldron RJ; Castel AM; Munana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2018 Oct; 41(5):638-643. PubMed ID: 29761906
[TBL] [Abstract][Full Text] [Related]
3. Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside.
Menaut P; Landart J; Behr S; Lanore D; Trumel C
Vet Rec; 2008 Feb; 162(8):241-5. PubMed ID: 18296666
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology.
Levitin HA; Foss KD; Li Z; Reinhart JM; Hague DW; Fan TM
J Vet Pharmacol Ther; 2021 Sep; 44(5):696-704. PubMed ID: 34080695
[TBL] [Abstract][Full Text] [Related]
5. Cytosine arabinoside constant rate infusion without subsequent subcutaneous injections for the treatment of dogs with meningoencephalomyelitis of unknown origin.
Stee K; Broeckx BJG; Targett M; Gomes SA; Lowrie M
Vet Rec; 2020 Nov; 187(11):e98. PubMed ID: 32862133
[TBL] [Abstract][Full Text] [Related]
6. Effect of a constant rate infusion of cytosine arabinoside on mortality in dogs with meningoencephalitis of unknown origin.
Lowrie M; Thomson S; Smith P; Garosi L
Vet J; 2016 Jul; 213():1-5. PubMed ID: 27240905
[TBL] [Abstract][Full Text] [Related]
7. Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology.
Early PJ; Crook KI; Williams LM; Davis EG; Muñana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2017 Aug; 40(4):411-414. PubMed ID: 27641693
[TBL] [Abstract][Full Text] [Related]
8. Clinical presentation, diagnostic findings, prognostic factors, treatment and outcome in dogs with meningoencephalomyelitis of unknown origin: A review.
Cornelis I; Van Ham L; Gielen I; De Decker S; Bhatti SFM
Vet J; 2019 Feb; 244():37-44. PubMed ID: 30825893
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation, diagnostic findings and outcome in dogs diagnosed withpresumptive spinal-only meningoen-cephalomyelitis of unknown origin.
Cornelis I; Volk HA; Van Ham L; De Decker S
J Small Anim Pract; 2017 Mar; 58(3):174-182. PubMed ID: 28267222
[TBL] [Abstract][Full Text] [Related]
10. Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogs.
Zarfoss M; Schatzberg S; Venator K; Cutter-Schatzberg K; Cuddon P; Pintar J; Weinkle T; Scarlett J; Delahunta A
J Small Anim Pract; 2006 Oct; 47(10):588-95. PubMed ID: 17004951
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs.
Vazquez Fuster IB; Taylor AR; Smith AN; Duran SH; Ravis WR; Jasper SL; Arnold RD
J Vet Intern Med; 2020 Jul; 34(4):1563-1569. PubMed ID: 32442344
[TBL] [Abstract][Full Text] [Related]
12. Novel subcutaneous cytarabine infusion with the Omnipod system in dogs with meningoencephalomyelitis of unknown etiology.
Mancini SL; Early PJ; Slater BM; Olby NJ; Mariani CL; Munana KR; Woelfel CW; Schacher JA; Zhong L; Messenger KM
Am J Vet Res; 2022 Jul; 83(9):. PubMed ID: 35895763
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid monotherapy versus combined cytarabine continuous rate infusion and corticosteroid therapy in dogs with meningoencephalitis of unknown origin: A blinded, randomized, controlled trial.
Jones BS; Liebel FX; Fadda A; Martin S; Lawn R; Lazzerini K; Harcourt-Brown T
J Vet Intern Med; 2024; 38(3):1618-1625. PubMed ID: 38700360
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
[TBL] [Abstract][Full Text] [Related]
15. Treatment of granulomatous meningoencephalomyelitis in a dog.
Nuhsbaum MT; Powell CC; Gionfriddo JR; Cuddon PA
Vet Ophthalmol; 2002 Mar; 5(1):29-33. PubMed ID: 11940245
[TBL] [Abstract][Full Text] [Related]
16. Treatment of meningoencephalitis of unknown origin in a dog.
Behr S; Llabrés-Días FJ; Radaelli ST
Vet Rec; 2009 May; 164(20):627-9. PubMed ID: 19448257
[No Abstract] [Full Text] [Related]
17. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC
Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843
[TBL] [Abstract][Full Text] [Related]
18. Retrospective evaluation of combined mycophenolate mofetil and prednisone treatment for meningoencephalomyelitis of unknown etiology in dogs: 25 cases (2005-2011).
Barnoon I; Shamir MH; Aroch I; Bdolah-Abram T; Srugo I; Konstantin L; Chai O
J Vet Emerg Crit Care (San Antonio); 2016; 26(1):116-24. PubMed ID: 26458162
[TBL] [Abstract][Full Text] [Related]
19. The bioavailability of cytarabine in dogs with meningoencephalitis of unknown etiology through iontophoresis and rectal delivery.
Mancini SL; Early PJ; Pastina BO; Olby NJ; Mariani CL; Munana KR
Open Vet J; 2021; 11(1):36-38. PubMed ID: 33898281
[TBL] [Abstract][Full Text] [Related]
20. Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs.
Zwueste DM; Vernau KM; Vernau W; Pypendop BH; Knych HK; Rodrigues CA; Kol A; Questa M; Dickinson PJ
J Vet Intern Med; 2023; 37(6):2429-2442. PubMed ID: 37670479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
